Stocks · News reference
Preliminary Update on 2026 Guidance2Based on preliminary third-quarter results, Bausch + Lomb and Bausch Health currently expect to raise full-year 2026 adjusted EBITDA excluding Acquired IPR&D1 guidance.3 The
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Bausch Health and its Salix Pharmaceuticals division will present research on cirrhosis trends and severe alcohol-associated hepatitis at the American Association for the Study of Liver Diseases' The Liver Meeting 2026.
During its third-quarter 2026 earnings call, Bausch Health Companies Inc. addressed potential strategic options regarding its ownership stake in Bausch + Lomb Corporation.
Frederick Munsch, Senior Vice President, Controller, and Chief Accounting Officer of Bausch + Lomb, sold 112,015 common shares for approximately $2.29 million.
HC Wainwright & Co. has downgraded Bausch + Lomb Corporation from Buy to Neutral while increasing its price target to $22 from $21.
A recent survey of 14 analysts by FactSet has resulted in an upward revision of Bausch + Lomb Corporation's 2026 earnings per share (EPS) estimate and price target.
Stocks rallied on strong earnings and raised guidance, led by Huntington Ingalls, Porch, Teladoc and Crocs, despite the Dow falling 150 points.